USP39 and prostate carcinoma: It is noteworthy that prostate cancer cell proliferation is inhibited when SUMO binds to sites on USP39, but the attraction phenomenon can be reversed when these SUMO binding sites are mutated (58), suggesting that SUMO modification can inhibit the tumor-promoting effects of USP39.